

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: McCarthy, et al.  
Serial No.: 10/762,928  
Filed: August 5, 2004  
For: *In Vitro* Method for Disassembly/Reassembly of Papillomavirus Virus-Like Particles (VLPs), Homogeneous VLP and Capsomere Compositions Produced by Said Methods; Use Thereof as Vehicle for Improved Purification, and Delivery of Active Agents  
Patent No.: 7,351,533  
Issued: April 1, 2008

Commissioner for Patents  
Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
MAY 25 2010  
PATENT EXTENSION  
OPLA

Mail Stop Hatch – Waxman PTE

Sir:

Pursuant to a telephone conversation with Mary Till of the Office of Patent Legal Administration on May 7, 2010, please find enclosed a copy of a letter from Marcus J.W. Dalton, Vice President, Global Head, Bio Patents, of GlaxoSmithKline to Scott Alban of MedImmune, Inc. In such letter, Mr. Dalton states that GlaxoSmithKline authorizes MedImmune, Inc. to rely upon the activities of GlaxoSmithKline before the FDA in submitting an application for an Extension of the Patent Term of its '533 patent.

Kindly charge any fees to Deposit Account No. 03-0678.

Respectfully submitted,



Raymond J. Lillie  
Registration No. 31,778